This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...
The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...
The U.S. Food and Drug Administration ... type 2 diabetes and Zepbound for weight loss, was in short supply for more than two years. But the drugmaker Eli Lilly is “currently meeting or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback